The transcription factor SALL4 regulates stemness of EpCAM-positive hepatocellular carcinoma.

[1]  P. Illei,et al.  Immunohistochemical expression of SALL4 in hepatocellular carcinoma, a potential pitfall in the differential diagnosis of yolk sac tumors. , 2013, Human pathology.

[2]  Kol Jia Yong,et al.  Oncofetal gene SALL4 in aggressive hepatocellular carcinoma. , 2013, New England Journal of Medicine.

[3]  S. Thorgeirsson,et al.  Sall4 in "stemness"-driven hepatocarcinogenesis. , 2013, The New England journal of medicine.

[4]  X. Wang,et al.  Sal‐like protein 4 (SALL4), a stem cell biomarker in liver cancers , 2013, Hepatology.

[5]  Kol Jia Yong,et al.  Targeting transcription factor SALL4 in acute myeloid leukemia by interrupting its interaction with an epigenetic complex. , 2013, Blood.

[6]  Motoki Saito,et al.  Stemness-related Factor Sall4 Interacts with Transcription Factors Oct-3/4 and Sox2 and Occupies Oct-Sox Elements in Mouse Embryonic Stem Cells* , 2012, The Journal of Biological Chemistry.

[7]  Yasunori Sato,et al.  α-Fetoprotein-producing gastric carcinoma and combined hepatocellular and cholangiocarcinoma show similar morphology but different histogenesis with respect to SALL4 expression. , 2012, Human pathology.

[8]  X. Wang,et al.  Clinical implications of cancer stem cell biology in hepatocellular carcinoma. , 2012, Seminars in oncology.

[9]  Yupo Ma,et al.  Role of SALL4 in hematopoiesis , 2012, Current opinion in hematology.

[10]  Yupo Ma,et al.  Stem Cell Gene SALL4 Suppresses Transcription through Recruitment of DNA Methyltransferases* , 2011, The Journal of Biological Chemistry.

[11]  Yupo Ma,et al.  SALL4 is a robust stimulator for the expansion of hematopoietic stem cells. , 2011, Blood.

[12]  P. Wade,et al.  Cancer biology and NuRD: a multifaceted chromatin remodelling complex , 2011, Nature Reviews Cancer.

[13]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[14]  S. Kwon,et al.  Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. , 2011, Gastroenterology.

[15]  S. Orkin,et al.  Differential Roles of Sall4 Isoforms in Embryonic Stem Cell Pluripotency , 2010, Molecular and Cellular Biology.

[16]  M. Honda,et al.  Oncostatin m renders epithelial cell adhesion molecule-positive liver cancer stem cells sensitive to 5-Fluorouracil by inducing hepatocytic differentiation. , 2010, Cancer research.

[17]  Li Chai,et al.  A Novel SALL4/OCT4 Transcriptional Feedback Network for Pluripotency of Embryonic Stem Cells , 2010, PloS one.

[18]  R. Barrio,et al.  Regulation and function of Spalt proteins during animal development. , 2009, The International journal of developmental biology.

[19]  T. Ichisaka,et al.  Roles of Sall4 in the generation of pluripotent stem cells from blastocysts and fibroblasts , 2009, Genes to cells : devoted to molecular & cellular mechanisms.

[20]  Ha-won Jeong,et al.  Stem Cell Factor SALL4 Represses the Transcriptions of PTEN and SALL1 through an Epigenetic Repressor Complex , 2009, PloS one.

[21]  H. Nakauchi,et al.  Sall4 regulates cell fate decision in fetal hepatic stem/progenitor cells. , 2009, Gastroenterology.

[22]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[23]  Li Chai,et al.  Genome-wide analysis reveals Sall4 to be a major regulator of pluripotency in murine-embryonic stem cells , 2008, Proceedings of the National Academy of Sciences.

[24]  J. Visvader,et al.  Cancer stem cells in solid tumours: accumulating evidence and unresolved questions , 2008, Nature Reviews Cancer.

[25]  L. Fink,et al.  SALL4 is a key regulator of survival and apoptosis in human leukemic cells. , 2008, Blood.

[26]  Jin Woo Kim,et al.  EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. , 2008, Cancer research.

[27]  Xin Wei Wang,et al.  Activation of hepatic stem cell marker EpCAM by Wnt-beta-catenin signaling in hepatocellular carcinoma. , 2007, Cancer research.

[28]  J. McNamara.  Cancer Stem Cells , 2007, Methods in Molecular Biology.

[29]  L. Fink,et al.  Bmi-1 is a target gene for SALL4 in hematopoietic and leukemic cells , 2007, Proceedings of the National Academy of Sciences.

[30]  Irving L Weissman,et al.  Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. , 2006, Cancer research.

[31]  Christian Wilhelm,et al.  SALL4 is directly activated by TCF/LEF in the canonical Wnt signaling pathway. , 2006, Biochemical and biophysical research communications.

[32]  Li Chai,et al.  Sall4 modulates embryonic stem cell pluripotency and early embryonic development by the transcriptional regulation of Pou5f1 , 2006, Nature Cell Biology.

[33]  X. Chen,et al.  Sall4 Interacts with Nanog and Co-occupies Nanog Genomic Sites in Embryonic Stem Cells* , 2006, Journal of Biological Chemistry.

[34]  Michael Dean,et al.  Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.

[35]  C. St. Hilaire,et al.  Duane radial ray syndrome (Okihiro syndrome) maps to 20q13 and results from mutations in SALL4, a new member of the SAL family. , 2002, American journal of human genetics.

[36]  W. Reardon,et al.  Okihiro syndrome is caused by SALL4 mutations. , 2002, Human molecular genetics.

[37]  P. Nowell.  The clonal evolution of tumor cell populations. , 1976, Science.

[38]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[39]  M. Honda,et al.  Activation of lipogenic pathway correlates with cell proliferation and poor prognosis in hepatocellular carcinoma. , 2009, Journal of hepatology.